Abstract:With 19.3 million new cases and almost 10 million deaths in 2020, cancer has become a leading cause of death today. Curcumin and its analogues were found to have promising anticancer activity. Inspired by curcumin's promising anticancer activity, we prepared three semi-synthetic analogues by chemically modifying the diketone function of curcumin to its pyrazole counterpart. The curcumin analogues (3a–c) were synthesized by two different methods, followed by their DFT analyses to study the HOMO/LUMO configuration to access the stability of compounds (∆E = 3.55 to 3.35 eV). The curcumin analogues (3a–c) were tested for antiproliferative activity against a total of five dozen cancer cell lines in a single (10 μM) and five dose (0.001 to 100 μM) assays. 3,5-Bis(4-hydroxy-3-methoxystyryl)-1H-pyrazole-1-yl-(phenoxy)ethanone (3b) and 3,5-bis(4-hydroxy-3-methoxystyryl)-1H-pyrazole-1-yl-(2,4-dichlorophenoxy)ethanone (3c) demonstrated the most promising antiproliferative activity against the cancer cell lines with growth inhibitions of 92.41% and 87.28%, respectively, in a high single dose of 10 μM and exhibited good antiproliferative activity (%GIs > 68%) against 54 out of 56 cancer cell lines and 54 out of 60 cell lines, respectively. The compound 3b and 3c demonstrated the most potent antiproliferative activity in a 5-dose assay with GI50 values ranging between 0.281 and 5.59 μM and 0.39 and 0.196 and 3.07 μM, respectively. The compound 3b demonstrated moderate selectivity against a leukemia panel with a selectivity ratio of 4.59. The HOMO-LUMO energy-gap (∆E) of the compounds in the order of 3a > 3b > 3c, was found to be in harmony with the anticancer activity in the order of 3c ≥ 3b > 3a. Following that, all of the curcumin analogues were molecular docked against EGFR, one of the most appealing targets for antiproliferative activity. In a molecular docking simulation, the ligand 3b exhibited three different types of interactions: H-bond, π-π-stacking and π-cationic. The ligand 3b displayed three H-bonds with the residues Met793 (with methoxy group), Lys875 (with phenolic group) and Asp855 (with methoxy group). The π-π-stacking interaction was observed between the phenyl (of phenoxy) and the residue Phe997, while π-cationic interaction was displayed between the phenyl (of curcumin) and the residue Arg841. Similarly, the ligand 3c displayed five H-bonds with the residue Met793 (with methoxy and phenolic groups), Lys845 (methoxy group), Cys797 (phenoxy oxygen), and Asp855 (phenolic group), as well as a halogen bond with residue Cys797 (chloro group). Furthermore, all the compound 3a–c demonstrated significant binding affinity (−6.003 to −7.957 kcal/mol) against the active site of EGFR. The curcumin analogues described in the current work might offer beneficial therapeutic intervention for the treatment and prevention of cancer. Future anticancer drug discovery programs can be expedited by further modifying these analogues to create new compounds with powerful anticancer potentials.

Synthetic Curcumin Analogs in the Treatment of Cancer: A Literature Review

A Review of Curcumin and Its Derivatives as Anticancer Agents

Chemical Modification of Curcumin into Its Semi-Synthetic Analogs Bearing Pyrimidinone Moiety as Anticancer Agents

Synthesis and Antitumor Activity Study of Nitrogen-Containing Curcumin Derivatives

High Anti-cancer Activity, Low Animal Toxicity, and Structure Activity Relationships of Curcumin Analogs

Synthesis, DFT Analyses, Antiproliferative Activity, and Molecular Docking Studies of Curcumin Analogues

Curcumin: reclaiming the lost ground against cancer resistance

Curcuminoids as Cell Signaling Pathway Modulators: A Potential Strategy for Cancer Prevention

Nanocurcumin in cancer treatment: a comprehensive systematic review

Curcumin and its formulations: potential anti-cancer agents.

The Bright Side of Curcumin: A Narrative Review of Its Therapeutic Potential in Cancer Management

Targeting the Akt signaling pathway: Exploiting curcumin's anticancer potential

Therapeutic potential of novel formulated forms of curcumin in the treatment of breast cancer by the targeting of cellular and physiological dysregulated pathways

Clinical effects of curcumin in enhancing cancer therapy: A systematic review

Curcumin, its derivatives, and their nanoformulations: Revolutionizing cancer treatment

Curcumin in Cancer Prevention: Insights from Clinical Trials and Strategies to Enhance Bioavailability

The Cancer Chemopreventive and Therapeutic Potential of Tetrahydrocurcumin

Non-Curcuminoids from Turmeric and Their Potential in Cancer Therapy and Anticancer Drug Delivery Formulations

Curcumin and Related Compounds in Cancer Cells: New Avenues for Old Molecules

Curcumin in cancer therapy: Exploring molecular mechanisms and overcoming clinical challenges

Recent Progress in Studying Curcumin and Its Nano-preparations for Cancer Therapy